Proactive Investors - Run By Investors For Investors

ReNeuron phase 2 stem cell trials still on track

UK based clinical stage stem cell business, ReNeuron is moving ahead with its programme of clinical trials. The CFO, Michael Hunt, tells Proactiveinvestors the company is expecting initial results from its phase 2 trials of CTX for stroke victims by the end of 2015 with further data from that trial in the early part of 2016.

The company is also expecting the CLI programme to move out of phase I and into phase II in the second half of this year, and the phase I/II retinitis pigmentosa trial is expected to commence in the US this year.

ReNeuron raised £25 million in 2013 and has the funding in place to complete all of these clinical trials. It is also opening a world class cell manufacturing facility in South Wales.

 
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

Video
December 19 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use